Table 2 The association between GSTM3 expression and clinicopathologic features in patients with ESCC
Characteristic | GSTM3 expression in mRNA cohort | P# | GSTM3 expression in protein cohort | P# | ||||
|---|---|---|---|---|---|---|---|---|
Case | Low level (%) | High level (%) | Case | Low level (%) | High level (%) | |||
Gender | 0.618 | 0.691 | ||||||
Male | 135 | 65 (48.1) | 70 (51.9) | 137 | 84 (61.3) | 53 (38.7) | ||
Female | 49 | 26 (53.1) | 23 (46.9) | 110 | 71 (64.5) | 39 (35.5) | ||
Age | 1.000 | 0.356 | ||||||
≤ 60 | 104 | 51 (49.0) | 53 (51.0) | 138 | 83 (60.1) | 55 (39.9) | ||
> 60 | 80 | 40 (50.0) | 40 (50.0) | 109 | 72 (66.1) | 37 (33.9) | ||
Location | 0.543 | 0.567 | ||||||
Upper | 40 | 19 (47.5) | 21 (52.5) | 60 | 35 (58.3) | 25 (41.7) | ||
Middle | 100 | 47 (47.0) | 53 (53.0) | 161 | 105 (65.2) | 56 (34.8) | ||
Lower | 44 | 25 (56.8) | 19 (43.2) | 26 | 15 (57.7) | 11 (42.3) | ||
Differentiation | 0.024 | 0.004 | ||||||
Grade 1 | 46 | 17 (37.0) | 29 (63.0) | 23 | 12 (52.2) | 11 (47.8) | ||
Grade 2 | 92 | 44 (47.8) | 48 (52.2) | 157 | 90 (57.3) | 67 (42.7) | ||
Grade 3 | 46 | 30 (65.2) | 16 (34.8) | 67 | 53 (79.1) | 14 (20.9) | ||
pT category | 0.084 | 1.000 | ||||||
T1-2 | 44 | 27 (61.4) | 17 (38.6) | 84 | 53 (63.1) | 31 (36.9) | ||
T3-T4 | 140 | 64 (45.7) | 76 (54.3) | 163 | 102 (62.6) | 61 (37.4) | ||
pN category | 0.660 | 0.356 | ||||||
N0 | 100 | 51 (51.0) | 49 (49.0) | 136 | 89 (65.4) | 47 (34.6) | ||
N1-3 | 84 | 40 (47.6) | 44 (52.4) | 111 | 66 (59.5) | 45 (40.5) | ||
Pathological staging | 0.371 | 0.506 | ||||||
I | 14 | 9 (64.3) | 5 (35.7) | 19 | 13 (68.4) | 6 (31.6) | ||
II | 82 | 42 (51.2) | 40 (48.8) | 119 | 78 (65.5) | 41 (34.5) | ||
III-IV | 88 | 40 (45.5) | 48 (54.5) | 109 | 64 (58.7) | 45 (41.3) | ||